(1)
Bolodeoku, J.; Gbaa, T.; Morris, K.; Whitehead, S. Medicine Optimisation Using PCSK9 Monoclonal Antibodies (alirocumab and Evolocumab) Concerning the European Atherosclerosis Society (EAS) of < 1.8 mmol/L LDL Cholesterol Target in a Secondary Care Lipid Clinic. BJHMR 2023, 10, 91-102.